How much does it cost to develop a new drug? In Biogen's case, the answer is $2.5 billion. That's the figure that CEO George Scangos gave to the World Medical Innovation Forum in Boston for its much-hyped Alzheimer's drug, according to Bloomberg 's Michelle Fay Cortez.
The cost of multiple sclerosis drugs has skyrocketed over the past 20 years, and it's not just new drugs driving that increase. Not one MS drug has a list price of less than $50,000 per year in the U.S., and some treatments cost 7 times more now than they did in 1995, a new study found.
Remember the days when Biogen's Tecfidera was trumping analyst expectation after analyst expectation? Well, they're in the past--at least for now.
Riding high on some promising Phase I data, Biogen has mapped out a big late-stage program for its Alzheimer's disease treatment, making a risky bet that it can reverse decades of failure in the field.
The wearable fitness trend has exploded in the past few years. But for patients with certain medical conditions, wearables are more than hipster status symbols. The devices could help them manage chronic conditions. And for pharma companies, they could gather data to help tailor new treatments, track patient outcomes, and develop relationships with the people who use their meds.
Biogen turned heads around the industry last month with early data in which its plaque-destroying Alzheimer's treatment had a significant effect on patients' cognition, bucking a vexing trend for such antibodies. Among those paying close attention was Roche, which is now re-examining a pair of once-failed treatments.
PatientsLikeMe has struck a 5-year deal to support R&D at AstraZeneca. The agreement tops off a busy and important 12 months for the patient network, in which it has also expanded relationships with Biogen, Roche's Genentech and Swiss biopharma Actelion.
PatientsLikeMe and Biogen revealed promising results from a new study that shows wearable devices can help monitor individuals with MS over time, providing additional information to clinicians and potentially increasing adherence among patients.
A group of the world's leading drugmakers have joined the U.K.'s ambitious initiative to sequence the genomes of 100,000 Britons, mining the data with hopes of finding new pathways to treat cancer and rare diseases.
Biogen's latest evolution is more than just a nominal shift, according to its CEO, as the Big Biotech lops the Idec from its name and hopes to parlay its success in multiple sclerosis into some tough-to-treat diseases.